Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus - Wikidata - wikimedia - TriplyDB

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

http://www.wikidata.org/entity/Q27667750

about

Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens Emerging Vaccine Technologies A Blueprint for HIV Vaccine Discovery A New Scientific Paradigm may be Needed to Finally Develop an HIV Vaccine Structure-Based Design of Head-Only Fusion Glycoprotein Immunogens for Respiratory Syncytial Virus Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus Proof of principle for epitope-focused vaccine design Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design Protein Crystallography in Vaccine Research and Development Dengue: knowledge gaps, unmet needs, and research priorities Immunogenicity of membrane-bound HIV-1 gp41 membrane-proximal external region (MPER) segments is dominated by residue accessibility and modulated by stereochemistry.Computational tools for epitope vaccine design and evaluation Transplanting supersites of HIV-1 vulnerability.Options and obstacles for designing a universal influenza vaccine Peptides designed to spatially depict the Epstein-Barr virus major virion glycoprotein gp350 neutralization epitope elicit antibodies that block virus-neutralizing antibody 72A1 interaction with the native gp350 molecule Palivizumab epitope-displaying virus-like particles protect rodents from RSV challenge.Future opportunities for passive immunity against viral diseases.Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform Computational design of protein antigens that interact with the CDR H3 loop of HIV broadly neutralizing antibody 2F5.Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV Biomimetic monolayer-protected gold nanoparticles for immunorecognition High Resolution Mapping of Bactericidal Monoclonal Antibody Binding Epitopes on Staphylococcus aureus Antigen MntC.Adversomics: a new paradigm for vaccine safety and design.Addressing viral resistance through vaccines Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin.Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses.Advances in antiviral vaccine development.Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.Respiratory syncytial virus: current progress in vaccine development.Vaccine design: emerging concepts and renewed optimism.Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein.Recent advances in the development of subunit-based RSV vaccines.CD4+ T cells support establishment of RSV-specific IgG and IgA antibody secreting cells in the upper and lower murine respiratory tract following RSV infection.Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

P2860

Q26777382-2E3FED6F-A575-4249-860E-DBFA9C34F73D Q26783764-B2C1E940-D26D-483D-ADF8-CB747C3D04E0 Q26829865-04AFFA36-86CB-4BA0-8A3A-D5ED98DB6AB6 Q26830360-9AC6BFE8-B451-4018-B6BD-5C93A125AB9C Q27333522-4B3FCDCB-5360-41D6-BEDF-08334E95DF66 Q27677570-0FFBF654-FEEF-4E38-96FA-66E007D85580 Q27680499-E0D0A9E1-3BC3-4532-96E9-C23617FBE1E5 Q27681593-E0D21C77-9405-47A2-A06A-E082ED6B0BBF Q28075274-898E849B-9DF7-41AC-AEE4-C233C019C351 Q28087528-DF803FF7-7BB8-4216-AE0F-DC4D1EF02336 Q28729764-5924CDAC-C582-4D71-9138-04CB8E0B82CF Q30353709-9DD7F53F-4C25-48FB-9055-004A74BFBD8F Q30373339-519C51FF-994F-4DDF-A8EA-2DCB297BE9BF Q33854841-DCC934E5-584D-4689-9B4A-4565D3AC1600 Q34102290-CCBA271C-AFC2-453A-8AEC-CE97EEB49EC1 Q35488811-BF465442-8357-4D03-9BAD-97BC6532DD64 Q35535626-61F9C00C-49B8-4EAC-BAE1-EBB6E20632D8 Q35557110-34BD2B83-D882-4696-8A7C-012770251B5B Q35591551-6C2D3D8A-DD51-4A01-B296-D27FFD555E83 Q35624791-000FBAE7-9227-42BF-AC0D-0CDD11E5A246 Q35942829-8A8E3661-15A9-4CB3-AA34-5C8A38CBF727 Q36029158-A751FF80-EE41-4C5F-BDD3-3A8FFE772A63 Q36035568-CA094DFB-E737-4F84-825E-D544D483090F Q36149696-E7B80618-7CC1-4C33-A3C8-0E1A1008EB64 Q36242667-7B210B1B-2F1D-4E69-859C-F712A04B64A5 Q36304783-4FF9D462-FDD5-4400-ACA7-9FFE16672563 Q36353767-CC5E0652-C8D5-45F0-B8F8-522E8BAC7F32 Q36363177-96685431-1742-4E86-90BC-8837081567CF Q36693991-3C9646B8-75DD-4203-820F-C94EFB033BB8 Q37292398-4E99C8CA-D6D8-47A8-964B-68B16F6B56B8 Q37536191-138231FA-45AA-4092-9123-FBD2088BA762 Q38079432-A6C5807B-E8BB-4C1D-B6FF-2E91786142C2 Q38087785-BBE9AA66-9E56-460D-9009-8EC99AF081C5 Q38394731-949CD736-85B1-4608-93EB-0150B69E98D2 Q38617302-CCBB967F-0FA4-4D82-AC72-2FAC2977251B Q38836417-A6FC2BD1-5174-4D72-95F1-706214E34584 Q39170404-AFB990AE-30B0-450A-9631-3963792264CF Q40046506-1DEF2787-ECA3-44E6-AEB9-8A97E3233E12 Q40047887-A7A94130-9712-48F3-912D-395D007BA587 Q40565908-2DC747FE-3F74-44D1-A67D-853DC14BEED1

P2860

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

http://www.wikidata.org/entity/Q27667750

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Design and Characterization of ...... om Respiratory Syncytial Virus

@ast

Design and Characterization of ...... om Respiratory Syncytial Virus

@en

Design and Characterization of ...... om Respiratory Syncytial Virus

@nl

type

label

Design and Characterization of ...... om Respiratory Syncytial Virus

@ast

Design and Characterization of ...... om Respiratory Syncytial Virus

@en

Design and Characterization of ...... om Respiratory Syncytial Virus

@nl

prefLabel

Design and Characterization of ...... om Respiratory Syncytial Virus

@ast

Design and Characterization of ...... om Respiratory Syncytial Virus

@en

Design and Characterization of ...... om Respiratory Syncytial Virus

@nl

P1433

Q27667750-9008B183-C0B6-427B-9449-C6D5D2B652FF

P1476

Q27667750-98441432-32F7-4182-95BB-B1600DC7BDE4

P2093

Q27667750-1F9573B1-7CC5-4701-BDCF-D02B8EF55E44

Q27667750-47AC4676-2B00-4195-AE58-A6A83C55D333

Q27667750-BA6CDCA3-466D-4D86-9F52-274E0FAB5E8E

Q27667750-CB192DAC-8EFF-4D14-AD88-E3952F6D0762

Q27667750-CC09A226-AC47-4352-ADB1-545E9B5200D0

Q27667750-E144AB59-A963-459E-90EF-7780D2C6929F

P2860

Q27667750-05C187AE-25D1-4711-BFAC-5A98AEE2EA74

Q27667750-0A9C2E2B-A26E-4B1B-8D4D-58677E99B993

Q27667750-233F6C31-EFCF-4394-ADA0-6D9B5BAE807F

Q27667750-2FB46FB4-6381-4302-9C47-03505E5BC95D

Q27667750-4A2AB351-12FC-4722-B241-DA5601958384

Q27667750-4E560E13-D30A-4B05-BE13-FDA72E3A37EA

Q27667750-53210F06-9908-44B8-BF41-633D82B66FAF

Q27667750-60E19775-C829-43E7-AE6F-5CA7290CF6C1

Q27667750-61012ED5-E67C-4599-86FE-27BB81227EB7

Q27667750-71101788-F8A5-463F-9ADB-A136F71F6D35

P304

Q27667750-CD3F204A-9844-49CA-AB37-D769C1D36A8D

P31

Q27667750-A41E23D4-0639-444A-8438-86B7F110DC43

P3181

Q27667750-8E923E3B-B2C3-41FC-9C79-8828892FD23C

P356

Q27667750-C65B7B19-1AB5-44F4-A5F3-E3BA398385D2

P407

Q27667750-A09514D1-5AA5-4A70-9B41-42E21A4AC181

P433

Q27667750-4D92CC67-C226-446F-B96A-9448E236CE3D

P478

Q27667750-A7DC8E7E-09EB-44BF-A389-D68473798FF6

P50

Q27667750-ECD4260F-F559-474B-BC5D-62C5DC770700

P577

Q27667750-791DB3B0-CA1D-497D-9D33-6F54E0AB7FC3

P5875

Q27667750-C35B9150-90BE-4B07-A8D2-386E3A88ECF0

P698

Q27667750-348F78E3-60A2-468C-B041-7E0A3EB52B79

P932

Q27667750-015B855E-283C-4BE4-BC28-318ED2A1139A

P3181

P356

J.JMB.2011.04.044

P1433

Journal of Molecular Biology

P1476

Design and Characterization of ...... om Respiratory Syncytial Virus

@en

P2093

Bruno E Correia

http://www.w3.org/2001/XMLSchema#string

Jason S McLellan

http://www.w3.org/2001/XMLSchema#string

Man Chen

http://www.w3.org/2001/XMLSchema#string

Peter D Kwong

http://www.w3.org/2001/XMLSchema#string

William R Schief

http://www.w3.org/2001/XMLSchema#string

Yongping Yang

http://www.w3.org/2001/XMLSchema#string

P2860

The Protein Data Bank

Structural basis for recognition by an in vitro evolved affibody

Native protein sequences are close to optimal for their structures

MolProbity: all-atom contacts and structure validation for proteins and nucleic acids

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function

Structural basis of respiratory syncytial virus neutralization by motavizumab

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

Elicitation of structure-specific antibodies by epitope scaffolds

Coot: model-building tools for molecular graphics

Phasercrystallographic software

P304

853-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1284977

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.JMB.2011.04.044

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

409

http://www.w3.org/2001/XMLSchema#string

P50

Barney S. Graham

P577

2011-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51105150

http://www.w3.org/2001/XMLSchema#string

P698

21549714

http://www.w3.org/2001/XMLSchema#string

P932

3107930

http://www.w3.org/2001/XMLSchema#string